Oscar Health is rated a buy with a target price range of $45 to $49, driven by its scalable growth and margin expansion in the Affordable Care Act (ACA) market. The company grew its membership by 60%, significantly outperforming the overall ACA market which contracted by 13%, capturing a 30% market share and improving its medical loss ratio to 81.5%. Management projects a revenue compound annual growth rate (CAGR) above 20% through 2029, operating margins of 5-7%, and earnings per share (EPS) above $4, with the Lucie marketplace expected to be a key growth driver. Risks include regulatory changes, uncertain market growth, and dependence on premium subsidies, while upcoming Q4 results and Lucie segment disclosures are important near-term catalysts.
Oscar Health's strong growth story contrasts with its current trading pattern on Pluang, where the stock price is USD 29.60 as of Sep 27, 2026, 08:41 WIB, showing a 1-day gain of 2.53%. Despite the upbeat projections, Pluang data reveals a market cap of $9.14 billion and a 52-week trading range between $10.85 and $33.81. Notably, all recent order activity on Pluang is selling, which may reflect cautious investor sentiment despite the company's expansion plans.
